Yahoo Finance13d
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study ...
manilatimes17d
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II ...
pharmaphorum2d
ASH: MSD’s ROR1 drug hits the target in first-line lymphoma
The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.
pharmaphorum3d
MSD starts pivotal trial of ROR1 drug in first-line lymphoma
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...
PipelineReview.com13d
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed ...
Frontiers20d
Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia
1 Hematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy 2 Surgical Pathology and Cytopathology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy The ...